All Search Results
News Releases
Aug 12, 2026, 09:02 ET Philadelphia Sleep Physician Dr. Funke Afolabi-Brown Featured on FOX 29, Launches Free "Perimenopause Sleep Guide" for Women Struggling to Sleep in Midlife
standard sleep advice so often falls short for women in midlife, and what the evidence actually supports — including cognitive behavioral therapy for insomnia (CBT-I), addressing hot flashes and night sweats directly, ruling out sleep-disordered breathing, and aligning sleep timing with a woman's individual
More news about: The Restful Sleep Place
Aug 11, 2026, 07:50 ET SLENYTO® (melatonin extended-release tablets) is now available in Canada as a prescription treatment for insomnia in children and adolescents with autism spectrum disorder (ASD) and/or Smith-Magenis syndrome (SMS).
(melatonin extended-release tablets) is now available across Canada. SLENYTO® is approved as a prescription medicine in Canada for the treatment of insomnia in children and adolescents aged 2 to <18 years with autism spectrum disorder (ASD) and / or Smith-Magenis syndrome (SMS), where sleep hygiene
More news about: Kye Pharmaceuticals Inc.
Aug 10, 2026, 14:59 ET Insomnia Cookies Gives the Class of 2030 30,000 Free Freshman 6-Packs of Cookies
begins its next chapter, Insomnia Cookies wishes students the best — and looks forward to being there all year long for late-night study breaks, much-needed pick-me-ups, new-friend hangouts and every celebration along the way.ABOUT INSOMNIA COOKIESInsomnia Cookies is a rapidly expanding
More news about: Insomnia Cookies
Aug 10, 2026, 10:31 ET Major Depressive Disorder Market is Predicted to Grow During the Forecast Period (2026-2036) as Novel Antidepressants are Expected to Enter the Market | DelveInsight
said that among emerging therapies, seltorexant is expected to demonstrate moderate-to-strong uptake potential, particularly in MDD patients with insomnia and sleep-related symptoms, reflecting growing interest in orexin-targeted therapies.Major Depressive Disorder Market Analysis
More news about: DelveInsight Business Research, LLP
Aug 05, 2026, 09:00 ET Headlands Research Expands Pacific Northwest Presence with New Clinical Research Site in Bellingham, Washington
615,000 people within a 50-mile radius. Local physicians logged more than 1,200 diagnosis claims across depression, bipolar disorder, anxiety, and insomnia in 2025, a participant pool well-suited to Dr. Bogoyas's specialization. The site is expected to support neuropsychiatric and adjacent therapeutic
More news about: Headlands Research
Organizations
Resources
News Trends
Summer Eating, a (Fancy) Show, and Sweets/Snacks: The Latest Food News Trends
its Flavor of the Day lineup with two new custard flavors: Lemon Berry Layer Cake and Dark Chocolate PB Crunch. Insomnia Cookies announced that its ice cream line,